

PATIENT GUIDE

Tirzepatide for weight and metabolic health

How this once weekly medicine works, what the major trials showed, how the dose is built up, and what the safety information says.

COMPOUND	CLASS	ROUTE	STATUS	SOURCES
Tirzepatide	Incretin agonist	Weekly injection	FDA approved	29 · PMID linked

§ 01

Why we are talking about tirzepatide

Tirzepatide is one of the most thoroughly studied medicines in modern metabolic care. It is a once weekly injection that acts on two of the body's own appetite and blood sugar hormones at the same time, and in large clinical trials it produced substantial and sustained weight reduction.¹ It is approved by the U.S. Food and Drug Administration under two brand names, Zepbound and Mounjaro, for weight management, obstructive sleep apnea, type 2 diabetes and cardiovascular protection in type 2 diabetes.^{25 26}

This guide explains how tirzepatide works, what the trials showed, how the dose is built up, what the first months usually feel like, and what the safety information says. Every number is referenced at the end, with a link so you can read the source yourself.

20.9% **Average weight reduction at the highest dose.** Over 72 weeks in SURMOUNT-1, a trial of 2,539 adults with obesity or overweight, the 15 mg dose lowered body weight by 20.9 percent on average, compared with 3.1 percent on placebo.¹

3 **Years of trial follow up.** In SURMOUNT-1 participants with prediabetes, weight stayed 12.3 to 19.7 percent lower at 176 weeks, and type 2 diabetes was diagnosed in 1.3 percent on tirzepatide compared with 13.3 percent on placebo.²

4 **FDA approved uses.** Weight reduction and maintenance, and sleep apnea with obesity (Zepbound); type 2 diabetes, and cardiovascular risk reduction in type 2 diabetes (Mounjaro).^{25 26}

Once weekly **One injection a week.** Binding to albumin gives tirzepatide a half life of about five days, so a single weekly dose keeps a steady level in the blood after the first four weeks.²⁵

What tirzepatide is

After you eat, your gut releases two hormones called incretins. GIP (glucose dependent insulintropic polypeptide) and GLP-1 (glucagon like peptide 1) tell the pancreas that food is arriving, and they help signal to the brain that you are being fed.²⁵


Tirzepatide is a laboratory made peptide built on the GIP sequence and engineered to activate both the GIP receptor and the GLP-1 receptor. It carries two small substitutions in its amino acid chain and an attached fatty acid that lets it bind to albumin, the main protein in blood, which prolongs its half life and stretches its action across a full week.²⁵ ³ Because it acts on both receptors, it is often described as a dual agonist. ³

TIRZEPATIDE AT A GLANCE	
FEATURE	DETAILS
Name	Tirzepatide
Also called	Zepbound (weight management and sleep apnea), Mounjaro (type 2 diabetes). LY3298176 in early research ²⁵ ²⁶ ³
Structure	A peptide based on the GIP sequence, with two aminoisobutyric acid substitutions and a C20 fatty diacid attached at position 20. Molecular weight 4,813.53 Da ²⁵
Origin	Synthetic. Developed by Eli Lilly and Company; first FDA approval in 2022 ²⁶
Class	Dual GIP receptor and GLP-1 receptor agonist (an incretin medicine) ²⁵
How it is given	Injection under the skin once a week, by prefilled pen, vial or multidose KwikPen ²⁵

How tirzepatide works

Both GIP and GLP-1 receptors are found in the areas of the brain that regulate appetite, and in the pancreas. When tirzepatide activates them, several things happen together. People feel less hungry and eat less. The pancreas releases more insulin, but only when blood sugar is raised, which is why tirzepatide on its own rarely causes low blood sugar.⁴ The pancreas also releases less glucagon, the hormone that pushes blood sugar up, and the stomach empties more slowly.²⁵

Each of these effects has been measured in people. In a 28 week trial in adults with type 2 diabetes, tirzepatide 15 mg improved insulin secretion and insulin sensitivity more than semaglutide 1 mg, and lowered glucagon after meals.⁵ In the same trial it reduced appetite and the amount people ate at a test meal compared with placebo.⁶ The slowing of stomach emptying is strongest after the first doses and fades with continued treatment.⁷ ²⁵



One molecule, two hormone signals, several effects at once. Tirzepatide activates the receptors for both GIP and GLP-1, lowering appetite and food intake, releasing insulin only when blood sugar is raised, reducing glucagon, and slowing stomach emptying.²⁵ Each effect has been measured in human trials.^{5 6 7}

Tirzepatide does not act on the two receptors equally. Laboratory studies found that, at the doses used clinically, it engages the GIP receptor more fully than the GLP-1 receptor and signals through the GLP-1 receptor in a way that favors insulin release. Researchers think this balance may help explain why its effects exceed those of medicines that act on GLP-1 alone, though the full explanation is still being worked out.^{8 6}

The weight lost is mostly fat. In a body composition substudy of SURMOUNT-1 using DXA scans, fat mass fell by 33.9 percent and lean mass by 10.9 percent over 72 weeks, so about three quarters of the weight lost was fat and one quarter was lean tissue, the same proportions seen with the smaller weight loss on placebo.⁹

WHY THIS IS USEFUL TO KNOW

Tirzepatide works through appetite and metabolism, not through willpower, and it works best alongside the eating and activity changes it was tested with.²⁵ Because the stomach slows most at the start of each new dose, the dose is raised gradually, and most stomach side effects happen during those weeks.^{25 10} Because some of the weight lost is lean tissue, adequate protein and regular strength work are sensible companions to treatment, and worth discussing with your physician.

§ 04

What the research shows

Tirzepatide has been studied in two large phase 3 programs: SURMOUNT for weight and related conditions, and SURPASS for type 2 diabetes, with many thousands of participants followed for one to three years.

What is well established

Weight reduction. In SURMOUNT-1, adults without diabetes lost an average of 15.0, 19.5 and 20.9 percent of body weight at 5, 10 and 15 mg over 72 weeks, compared with 3.1 percent on placebo. Half of those on 10 mg and 57 percent of those on 15 mg lost 20 percent or more.¹ In adults who also had type 2 diabetes, weight fell by 12.8 and 14.7 percent at 10 and 15 mg.¹¹

Compared with semaglutide. In SURMOUNT-5, a 72 week head to head trial of 751 adults with obesity, tirzepatide lowered weight by 20.2 percent and semaglutide by 13.7 percent.¹² In type 2 diabetes, SURPASS-2 found tirzepatide lowered HbA1c more than semaglutide 1 mg at every dose.¹³

Sleep apnea. In SURMOUNT-OSA, adults with moderate to severe obstructive sleep apnea and obesity started with about 50 breathing interruptions per hour of sleep, and tirzepatide lowered this by 25 to 29 events per hour, compared with about 5 on placebo. ¹⁴ Between 42 and 50 percent of treated participants reached remission or mild sleep apnea without daytime sleepiness, compared with 14 to 16 percent on placebo. ²⁵

Type 2 diabetes and heart protection. Used on its own, tirzepatide lowered HbA1c by about 2 percentage points without clinically significant low blood sugar. ⁴ In SURPASS-CVOT, which enrolled 13,165 people with type 2 diabetes and cardiovascular disease, heart attack, stroke or cardiovascular death occurred in 12.2 percent on tirzepatide and 13.1 percent on dulaglutide, a medicine already shown to reduce these events, meeting the test for being at least as protective. ¹⁵ Mounjaro's label now includes this use. ²⁶

Treatment is long term. When people who had lost 20.9 percent on tirzepatide were switched to placebo in SURMOUNT-4, they regained 14.0 percent of their weight over the following year, while those who continued lost a further 5.5 percent. ¹⁶ SURMOUNT-MAINTAIN found that stepping down to the 5 mg dose kept much of the benefit, though less than staying on the full dose. ¹⁷

What is still being defined

Several promising uses are not yet approved. In SUMMIT, people with heart failure with preserved ejection fraction and obesity had fewer worsening heart failure events or cardiovascular deaths on tirzepatide (9.9 percent) than on placebo (15.3 percent), and felt better on a standard quality of life score. ¹⁸ In a phase 2 liver trial, 44 to 62 percent of people with fatty liver inflammation (MASH) confirmed by biopsy had it resolve, compared with 10 percent on placebo; larger trials are needed. ¹⁹ Whether tirzepatide lowers heart attacks, strokes and deaths in people with obesity who do not have diabetes is being tested in SURMOUNT-MMO, a trial of about 15,000 adults whose results have not yet been published. ²⁰ Researchers are also still defining the best long term maintenance dose for each person. ¹⁷

KEY HUMAN TRIALS BEHIND THE APPROVED USES All randomized. Doses are once weekly injections under the skin.			
STUDY	N	DESIGN	MAIN FINDING
SURMOUNT-1 ¹	2,539	72 weeks vs placebo, obesity or overweight without diabetes	Weight reduced 15.0, 19.5 and 20.9 percent at 5, 10 and 15 mg vs 3.1 percent
SURMOUNT-1, 3 years ²	1,032	176 weeks, participants with prediabetes	Weight 12.3 to 19.7 percent lower; diabetes in 1.3 vs 13.3 percent
SURMOUNT-4 ¹⁶	670	Withdrawal trial after 36 weeks of treatment	Continuing: further 5.5 percent reduction. Switching to placebo: 14.0 percent regained
SURMOUNT-MAINTAIN ¹⁷	378	Maintenance at full dose, 5 mg, or placebo	From the start, weight 21.9, 16.6 and 9.9 percent lower at 112 weeks
SURMOUNT-5 ¹²	751	72 weeks, open label vs semaglutide	Weight reduced 20.2 vs 13.7 percent
SURMOUNT-OSA ¹⁴	469	Two 52 week trials, sleep apnea with obesity	Breathing events fell 25.3 and 29.3 per hour vs 5.3 and 5.5
SURPASS-2 ¹³	1,879	40 weeks vs semaglutide 1 mg	HbA1c down 2.01 to 2.30 vs 1.86 points
SURPASS-CVOT ¹⁵	13,165	Type 2 diabetes with cardiovascular disease, vs dulaglutide	Major cardiovascular events 12.2 vs 13.1 percent; at least as protective

HOW WE WOULD SUMMARIZE IT

Tirzepatide is one of the best supported medicines available for weight and metabolic health. Large, well designed trials show substantial weight reduction, better blood sugar control, improvement in sleep apnea and, in type 2 diabetes, cardiovascular protection at least equal to an established medicine. The benefits last as long as treatment continues, and the stomach side effects are real but usually temporary. We think of it as a long term treatment and plan it that way with you.

§ 05

How tirzepatide is given

Tirzepatide is approved only as a once weekly injection under the skin.

Injection under the skin, once a week

The injection goes into the abdomen or thigh, or into the back of the upper arm if someone else gives it, and the site is rotated each week. It can be taken at any time of day, with or without food.²⁵ The medicine is absorbed steadily: blood levels peak about 24 hours after the dose, about 80 percent of the dose reaches the circulation, and a steady level is reached after four weekly doses. Absorption is similar from the abdomen, thigh and upper arm.²⁵

Zepbound and Mounjaro come as a single dose autoinjector pen, a single dose vial used with a syringe, and a multidose KwikPen or vial that holds four weekly doses. You and your physician will choose the presentation, and you will be shown how to use it before your first dose.^{25 26}

How the dose is built up

Every patient starts low and steps up gradually, because this reduces nausea and other stomach side effects. The schedule below is taken directly from the FDA label.²⁵

DOSE SCHEDULE ON THE FDA LABEL Once weekly injection under the skin.		
STAGE	WEEKLY DOSE	WHAT THE LABEL SAYS
Weeks 1 to 4	2.5 mg	Starting dose only. It is not a maintenance dose ²⁵
Week 5 onward	5 mg	First maintenance option ²⁵
Further steps	7.5, 10, 12.5, 15 mg	Increase by 2.5 mg only after at least 4 weeks on the current dose, guided by response and tolerability ²⁵
Maintenance	5, 10 or 15 mg	For weight reduction and long term maintenance. For sleep apnea, 10 or 15 mg ²⁵
Maximum	15 mg	For all adult indications ^{25 26}

If a dose is missed, it can be taken within four days; after that, skip it and take the next dose on the usual day. The injection day can be changed as long as doses are at least three days apart. If side effects are bothersome, your physician may hold a dose longer or choose a lower maintenance dose, as the label allows.²⁵

Tablets, drops under the tongue, and nasal sprays

There is no FDA approved oral, sublingual or nasal form of tirzepatide, and none of these forms has been tested in published human clinical trials. Some compounding pharmacies prepare sublingual drops or dissolving tablets, and a 2026 review of these products found that whether they work or are safe is largely unknown.²¹ Tirzepatide is a large peptide, it is not given into muscle, and everything we know about its benefits comes from the injection under the skin used in the trials and on both labels.^{25 26}

COMPARING THE OPTIONS		
	WEEKLY INJECTION UNDER THE SKIN	ORAL, SUBLINGUAL OR NASAL
FDA approved	YES Zepbound and Mounjaro ^{25 26}	NO
Half life	About 5 to 6 days ²⁵	Not studied in people
Human research	Large randomized trials ^{1 13}	None published ²¹
Common experience	Nausea, loose stools or constipation, mostly while the dose is rising ^{25 10}	Unknown

§ 06

What to expect

The first weeks. Many people notice a quieter appetite.⁶ Stomach side effects such as nausea, diarrhea or constipation are the most common experience, and in the trials they mostly occurred while the dose was being raised and eased over time.^{25 10} Having nausea did not change how much weight people lost, so feeling well is the goal, not a sign that the medicine is not working.¹⁰

The first six months. Most of the weight reduction happens over the first several months.²² People respond at different speeds: in SURMOUNT-1, 18 percent had lost less than 5 percent by week 12, yet 90 percent of that slower group had reached 5 percent or more by week 72.²³

Reaching a plateau. Weight loss gradually slows and levels off. In SURMOUNT-1 the median time to a plateau was about 24 to 36 weeks, depending on starting weight, and close to 9 in 10 participants had reached one by week 72.²² A plateau is expected, and it is when the conversation turns to maintenance.

Over the long term. The benefits last while treatment continues. People who stopped regained much of the weight they had lost over the following year,¹⁶ which is why tirzepatide is best planned as ongoing care. In one trial, stepping down to a lower dose kept part of the benefit.¹⁷

TELL US PROMPTLY IF

- Nausea, vomiting or diarrhea are severe or persistent, or you cannot keep fluids down. Dehydration is the main way kidney problems arise on this medicine.²⁵
- You have severe abdominal pain, especially if it spreads to your back.²⁵
- You notice a lump in your neck, persistent hoarseness, or trouble swallowing or breathing.²⁵

Safety

Tirzepatide's safety has been studied in thousands of people across its trial programs, and the FDA label describes it in detail. The most common side effects involve the digestive tract. In the pooled weight trials, 4.8, 6.3 and 6.7 percent of people on 5, 10 and 15 mg stopped because of side effects, compared with 3.4 percent on placebo.²⁵

MOST COMMON SIDE EFFECTS IN THE WEIGHT TRIALS Percent of participants, from the Zepbound label (selected; abdominal pain and indigestion each occurred in 9 to 10 percent, and allergic type reactions, belching, reflux and dizziness in 4 to 5 percent).				
SIDE EFFECT	PLACEBO	5 MG	10 MG	15 MG
Nausea	8	25	29	28
Diarrhea	8	19	21	23
Vomiting	2	8	11	13
Constipation	5	17	14	11
Injection site reactions	2	6	8	8
Fatigue	3	5	6	7
Hair loss	1	5	4	5

The boxed warning. In rats, tirzepatide caused thyroid C cell tumors. It is not known whether this happens in people, because the relevance of the rodent finding to humans has not been determined. For this reason, tirzepatide must not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and it must not be used after a serious allergic reaction to tirzepatide.²⁵

Other warnings on the label. Stomach side effects are occasionally severe (1.7 to 3.1 percent compared with 1 percent on placebo), and tirzepatide is not recommended with severe gastroparesis. Dehydration from vomiting or diarrhea can lead to kidney injury. Gallbladder inflammation occurred in 0.7 percent compared with 0.2 percent on placebo. Confirmed pancreatitis occurred in 0.2 percent of both the tirzepatide and placebo groups in the weight trials. Severe allergic reactions are rare (0.1 percent). Low blood sugar is uncommon on tirzepatide alone but more likely with insulin or a sulfonylurea. In type 2 diabetes, rapid improvement in blood sugar can temporarily worsen diabetic eye disease. Because the stomach empties slowly, food can remain in the stomach during anesthesia.²⁵

Contraception and pregnancy. Tirzepatide can reduce the effect of birth control pills. The label advises switching to a method that is not taken by mouth, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Tirzepatide should be stopped when a pregnancy is recognized.²⁵

Hair and mood. Hair thinning was linked to weight loss, was reported mainly in women (7.1 percent compared with 0.5 percent of men), and led no one to stop treatment.²⁵ In more than 4,000 SURMOUNT participants without major psychiatric illness, tirzepatide did not increase depression scores, and suicidal thoughts were reported at the same rate as placebo (0.6 percent).²⁴

TELL YOUR PHYSICIAN BEFORE STARTING IF ANY OF THESE APPLY

- You or a family member has had medullary thyroid cancer, or you have MEN 2.
- You have had pancreatitis, gallbladder disease, severe gastroparesis or another significant digestive condition.
- You have type 2 diabetes, especially if you use insulin or a sulfonylurea, or you have diabetic eye disease.
- You have kidney disease, or you are prone to dehydration.
- You are pregnant, planning a pregnancy, breastfeeding, or use birth control pills.
- You have a surgery or procedure planned.
- You have had a serious allergic reaction to tirzepatide or to any GLP-1 medicine, or you already take one.
- You take any prescription medication, over the counter product or supplement. Please bring the full list.

The longest published follow up in the weight trials is about three years, with no new safety signals.² Data spanning a decade or more do not yet exist, and a large outcome trial in people with obesity without diabetes is still under way.²⁰ That is one reason we review your treatment regularly rather than simply renewing it.

§ 08

Is this right for you

Zepbound is approved for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight related condition such as high blood pressure, high cholesterol or sleep apnea, and for adults with obesity and moderate to severe sleep apnea.²⁵ ¹ Your consultation is where we work out whether it fits your health and your other medicines.

Before we begin

- | | |
|--------------------------|---|
| ☐ | A review of your medical history, current medications and supplements |
| ☐ | Your weight, waist measurement, blood pressure and heart rate |
| ☐ | Baseline bloodwork, so that anything we see later can be compared against a starting point |
| ☐ | A clear note of what you are hoping to achieve, written down, so we can tell together whether it worked |

If your evaluation points to a specific contributor to weight gain, such as a thyroid problem or a medication effect, we will address it as part of your plan, alongside the eating and activity changes tirzepatide was studied with.²⁵

Reviewing your progress

We will reassess against your documented starting point once you are on a steady dose. If you are doing well, we will plan how to maintain it. If side effects are limiting you, we can hold or lower the dose. If you and your physician decide to stop, we will plan for that together, since weight tends to return after stopping.¹⁶ You are welcome to raise any of this at any time.

QUESTIONS WORTH ASKING US

Which dose would you aim for in my situation, and how quickly would we get there? How will we protect muscle while I lose weight? What should I do if the nausea is hard to manage? What is the plan if my weight plateaus earlier than expected? What would happen if I needed to stop? We are glad to answer all of these, and a good clinic should welcome them.

§ 09

Regulatory status, stated plainly

Tirzepatide is an FDA approved medicine. As Zepbound, it is approved, together with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.²⁵ As Mounjaro, it is approved to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of these events.²⁶

Compounded tirzepatide is not FDA approved. Pharmacies were permitted to compound it while it was on the FDA drug shortage list. The FDA determined the shortage was resolved in October 2024, confirmed this in December 2024, and ended the transition periods on 18 February 2025 for state licensed pharmacies and 19 March 2025 for outsourcing facilities. Since then, pharmacies may not regularly make what are essentially copies of the approved product unless the prescriber documents a change that makes a significant difference for that individual patient.²⁷ On 1 May 2026 the FDA also proposed not to add tirzepatide to the list of substances outsourcing facilities may compound from bulk ingredients; that proposal is not yet final.²⁸

For athletes, tirzepatide is not on the World Anti-Doping Agency Prohibited List. Since 1 January 2026 it has been part of WADA's Monitoring Program, which tracks use in sport without penalty.²⁹ Athletes who are tested should confirm current rules with their governing body.

If you would like details about the preparation used in your treatment, please ask.

References

Every source below is indexed in PubMed or published by the FDA or WADA

- 1 **Jastreboff AM, et al.** Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2022;387(3):205-216. [PMID 35658024](#) · SURMOUNT-1
- 2 **Jastreboff AM, et al.** Tirzepatide for obesity treatment and diabetes prevention. *N Engl J Med.* 2025;392(10):958-971. [PMID 39536238](#) · SURMOUNT-1, 3 year analysis
- 3 **Coskun T, et al.** LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Mol Metab.* 2018;18:3-14. [PMID 30473097](#)
- 4 **Rosenstock J, et al.** Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet.* 2021;398(10295):143-155. [PMID 34186022](#)

- 5 **Heise T, et al.** Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Lancet Diabetes Endocrinol. 2022;10(6):418-429. [PMID 35468322](#)

- 6 **Heise T, et al.** Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes.
Diabetes Care. 2023;46(5):998-1004. [PMID 36857477](#)

- 7 **Urva S, et al.** The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab. 2020;22(10):1886-1891. [PMID 32519795](#)

- 8 **Willard FS, et al.** Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
JCI Insight. 2020;5(17):e140532. [PMID 32730231](#) · laboratory and islet studies

- 9 **Look M, et al.** Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes Obes Metab. 2025;27(5):2720-2729. [PMID 39996356](#)

- 10 **Rubino DM, et al.** Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Diabetes Obes Metab. 2025;27(4):1826-1835. [PMID 39789843](#)

- 11 **Garvey WT, et al.** Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet. 2023;402(10402):613-626. [PMID 37385275](#)

- 12 **Aronne LJ, et al.** Tirzepatide as compared with semaglutide for the treatment of obesity.
N Engl J Med. 2025;393(1):26-36. [PMID 40353578](#) · SURMOUNT-5

- 13 **Frias JP, et al.** Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.
N Engl J Med. 2021;385(6):503-515. [PMID 34170647](#) · SURPASS-2

- 14 **Malhotra A, et al.** Tirzepatide for the treatment of obstructive sleep apnea and obesity.
N Engl J Med. 2024;391(13):1193-1205. [PMID 38912654](#) · SURMOUNT-OSA

- 15 **Nicholls SJ, et al.** Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes.
N Engl J Med. 2025;393(24):2409-2420. [PMID 41406444](#) · SURPASS-CVOT

- 16 **Aronne LJ, et al.** Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.
JAMA. 2024;331(1):38-48. [PMID 38078870](#)

- 17 **Horn DB, et al.** Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet. 2026;407(10545):2305-2318. [PMID 42119587](#)

- 18 **Packer M, et al.** Tirzepatide for heart failure with preserved ejection fraction and obesity.
N Engl J Med. 2025;392(5):427-437. [PMID 39555826](#) · SUMMIT

- 19 **Loomba R, et al.** Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.
N Engl J Med. 2024;391(4):299-310. [PMID 38856224](#) · SYNERGY-NASH

- 20 **Lam CSP, et al.** Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial.
Obesity (Silver Spring). 2025;33(9):1645-1656. [PMID 40545827](#)

- 21 **Belcourt J, Sapowadia A, White CM.** Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown.
Ann Pharmacother. 2026;60(9):902-906. [PMID 41689811](#)

- 22 **Horn DB, et al.** Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
Clin Obes. 2025;15(3):e12734. [PMID 39800653](#)

23

Ard J, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1.
Diabetes Obes Metab. 2025;27(9):5064-5071. [PMID 40677091](#)

24

Wadden TA, et al. Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT.
Obesity (Silver Spring). 2026;34(3):565-578. [PMID 41537305](#)

25

Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide. Revised 08/2026.
U.S. FDA approved labeling, DailyMed (version published 2 September 2026): [dailymed.nlm.nih.gov](#). Accessed 26 September 2026.

26

Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information. Revised 08/2026.
U.S. FDA approved labeling, DailyMed (version published 2 September 2026): [dailymed.nlm.nih.gov](#). Accessed 26 September 2026.

27

U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
Content current as of 1 April 2026. [fda.gov](#). Accessed 26 September 2026.

28

U.S. Food and Drug Administration. List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act.
Federal Register. 1 May 2026;91 FR 23431. Comment period extended to 30 July 2026. [federalregister.gov](#).

29

World Anti-Doping Agency. The 2026 Monitoring Program.
In effect from 1 January 2026. [wada-ama.org](#). Accessed 26 September 2026.



IMPORTANT NOTICE

This document is patient education prepared by Regen Therapy MD. It is not medical advice, not a prescription, and not a promise of any clinical outcome. Tirzepatide is approved by the U.S. Food and Drug Administration as Zepbound, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with a weight related condition and to treat moderate to severe obstructive sleep apnea in adults with obesity, and as Mounjaro, for type 2 diabetes in adults and children 10 years and older and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk; compounded tirzepatide is not FDA approved. Individual results vary, and no outcome can be predicted from the studies cited here.

Clinical services are provided by the supervising physician entity. Regen Therapy MD and Family MSO Holdings LLC provide management and administrative services and do not practice medicine, employ physicians in the practice of medicine, or influence clinical judgment. All treatment decisions are made solely by your licensed treating physician.

Do not begin, stop, or change any medication or supplement based on this document. Discuss it with your physician, and disclose every prescription drug, over the counter product, and supplement you take.

PATIENT SIGNATURE

DATE

REVIEWING PHYSICIAN

RTMD-WP-024 · Version 1.0 · 26 September 2026 · Next scheduled literature review: March 2027 · Prepared with sources indexed in PubMed and FDA public records.